A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-12 and is reviewed periodically as new material appears.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Long-lived fission products (LLFPs) are radioactive materials with a long half-life (more than 200,000 years) produced by nuclear fission of uranium and plutonium. Because of their persistent radiotoxicity, it is necessary to isolate them from humans and the biosphere and to confine them in nuclear waste repositories for geological periods of time. The focus of this article is radioisotopes (radionuclides) generated by fission reactors.
to improve glycemic control when metformin with or without sulphonylurea (SU) and either saxagliptin or dapagliflozin does not provide adequate glycemic control. when already being treated with metformin and saxagliptin and dapagliflozin.
==== Persecution of the Yemenite Jewish community ==== The Houthis have been accused of expelling or restricting members of the rural Yemeni Jewish community, which had about 50 remaining members. Reports of abuse include Houthi supporters bullying or attacking the country's Jews. Houthi officials have denied any involvement in the harassment, asserting that under Houthi control, Jews in Yemen would be able to live and operate freely as any other Yemeni citizen. "Our problems are with Zionism and the occupation of Palestine, but Jews here have nothing to fear," said Fadl Abu Taleb, a spokesman for the Houthis. Despite insistence by Houthi leaders that the movement is not sectarian, a Yemeni Jewish rabbi has reportedly said that many Jews remain terrified by the movement's slogan. As a result, Yemeni Jews reportedly retain a negative sentiment towards the Houthis, who they allege have committed persecutions against them. According to Israeli Druze politician Ayoob Kara, Houthi militants had given an ultimatum telling Jews to "convert to Islam or leave Yemen". In March 2016, a UAE-based newspaper reported that one of the Yemeni Jews who emigrated to Israel in 2016 was fighting with the Houthis. In the same month, a Kuwaiti newspaper, al-Watan, reported that a Yemeni Jew named Haroun al-Bouhi was killed in Najran while fighting with the Houthis against Saudi Arabia. The Kuwaiti newspaper added that the Yemeni Jews had a good relationship with Ali Abdullah Saleh, who was at that time allied with the Houthis and was fighting on different fronts with them.
=== Physiological factors === Physiological changes in nursing women, including an unusual milk supply and blocked milk ducts, cause nipple or breast ache. An oversupply of breast milk is caused by overactive milk expression. Hence, the excess milk accumulates, leading to breast engorgement and pain. On the other hand, milk supply will be lowered by prolonged breastfeeding, high pumping pressure and overly vigorous breast massage. Blocked milk ducts refers to lactiferous ducts' blockage at the nipple pore or deeper breast tissue. It hampers an adequate drainage of milk and causes breast mass, engorgement, redness, a nipple bleb and subsequent pain.
It's this relationship and bond that I never wanted to break and I'm really proud that I haven't because it has been difficult at times." She has said that she hopes to "be making baking videos until I'm 90 years old." In 2021, she said in a Forbes interview "that around 60 hours of work go into a typical cooking video," due to the amount of time needed to experiment, assemble, bake, and film.
Sources: en.wikipedia.org
Data published by Halifax Bank indicates that UK house prices have fallen at the fastest rate since 2011, with a 2.6% fall in the last year. A man in his 20s, known publicly only as LXB, becomes the first alleged neo-Nazi in the UK to be placed under special government powers for monitoring and controlling suspected terrorists. Following his trial and conviction at Nottingham Crown Court, Jamie Barrow is sentenced to life imprisonment with a minimum term of 44 years for the murders of a mother and her two children, who died after he set their flat on fire. Empire Cinemas collapses into administration, with the immediate closure of six of its outlets and the remainder at risk of closure. A story printed in The Sun alleges that an unnamed BBC presenter paid a 17-year-old for sexually explicit photos. In response the BBC says it is investigating and that the presenter is not scheduled to be on air in the coming days. 8 July Rishi Sunak reaffirms the UK's opposition to the use of cluster munitions, as the United States announces it will send the widely banned weapons to Ukraine, where the invasion has reached its 500th day. Thunderstorms affect parts of the UK as a brief hot spell comes to an end. 9 July – The Sun prints fresh allegations about an unnamed BBC presenter, alleging that he stripped down to his underpants during a video call to the teenager. Several male public figures associated with the BBC speak out to say they are not the individual concerned.
== Complexity of the problem == After genomics and transcriptomics, proteomics is the next step in the study of biological systems. It is more complicated than genomics because an organism's genome is more or less constant, whereas proteomes differ from cell to cell and from time to time. Distinct genes are expressed in different cell types, which means that even the basic set of proteins produced in a cell must be identified. In the past this phenomenon was assessed by RNA analysis, which was found to lack correlation with protein content. It is now known that mRNA is not always translated into protein, and the amount of protein produced for a given amount of mRNA depends on the gene it is transcribed from and on the cell's physiological state. Proteomics confirms the presence of the protein and provides a direct measure of its quantity.
In the 1960s, Australia - particularly Queensland - launched the first awareness campaign on the dangers of ultraviolet (UV) radiation in the spirit of primary prevention. In the 1980s, many countries in Europe and overseas initiated similar UV protection campaigns. UV radiation has a thermal effect on the skin and eyes and can lead to skin cancer (malignant melanoma) and eye inflammation or cataracts. To protect the skin from harmful UV radiation, such as photodermatosis, acne aestivalis, actinic keratosis or urticaria solaris, normal clothing, special UV protective clothing (SPF 40-50) and high SPF sunscreen can be used. The Australian-New Zealand Standard (AS/NZS 4399) of 1996 measures new textile materials in an unstretched and dry state for the manufacture of protective clothing worn while bathing, especially by children, and for the manufacture of shading textiles (sunshades, awnings). The UV Standard 801 assumes a maximum radiation intensity with the solar spectrum in Melbourne, Australia, on January 1 of a year (at the height of the Australian summer), the most sensitive skin type of the wearer, and under wearing conditions. As the solar spectrum in the northern hemisphere differs from that in Australia, the measurement method according to the European standard EN 13758-1 is based on the solar spectrum of Albuquerque (New Mexico, USA), which corresponds approximately to that of southern Europe. To protect your eyes, wear sunglasses with UV protection or special goggles that also shield the sides to prevent snow blindness.
=== Magnetotaxis === The movement and orientation of "Ca. M. multicellularis" appears to be altered by many external stimuli as it undergoes magnetotaxis, photokinesis, negative phototaxis and potentially helical klinotaxis. The organism contains multiple internal magnetosomes, membrane-bound structures containing magnetic nanocrystals. In "Ca. M. multicellularis" these crystals are greigite (Fe3S4) but in most other species of multicellular magnetotactic bacteria (MMB) the crystals are magnetite (Fe3O4). These magnetosomes are organised in linear chains that allow the consortium to orient itself along the Earth's geomagnetic field. In samples from the Southern Hemisphere, "Ca. M. multicellularis" exhibits a preference for south-facing orientation while swimming. In weak magnetic fields, under 80 μT, "Ca. M. multicellularis" behaves differently to other magnetotactic bacteria. Under fields close to or weaker than Earth's geomagnetic field, its trajectories appear significantly scattered away from the exact magnetic field line. In these situations, movement relies mostly on a combination of other environmental factors and the direction of the magnetic field line does not fully control the final swimming direction.
3,114km of high-pressure petroleum and gas pipelines An inland accumulation facility at Jameson Park, Gauteng (TM2), with a capacity of 180Ml A tank farm in Tarlton, Gauteng, for storage and distribution via rail and road, with a capacity of 29Ml A coastal terminal at Island View in Durban, for continuously supplying jet fuel to O.R. Tambo International Airport The Transnet pipeline network transports over 80% of refined fuel products for use in the inland market, and over 70% of the jet fuel used at O.R. Tambo International Airport. Approximately three-quarters of South Africa's fuel imports flow through Island View Precinct, which forms part of the Port of Durban. The Precinct serves as the country's main fuel storage and supply hub. Data for Transnet's pipeline fuel logistics is in the table below.
Sources: en.wikipedia.org
On October 21, 2025, Gallrein announced his candidacy for the United States House of Representatives for Kentucky's 4th congressional district, challenging seven-term incumbent Thomas Massie in the Republican primary. Massie had held the seat since 2012, and was considered to be popular within the district; in 2024 he had won the Republican primary with 76% of the vote, and the general election with 99.6% of the vote. President Donald Trump endorsed Gallrein on October 17, 2025. The primary was the most expensive congressional primary in U.S. history, costing over $25 million. Gallrein won the Republican nomination on May 19, 2026, 54.9%–45.1%, winning 19 of the 21 counties that voted. After the race against Massie was called in Gallrein's favor, Gallrein said: "It was a David versus Goliath. I was the underdog." Gallrein will face Democrat Melissa Strange in the general election on November 3, 2026.
=== Normal, prediabetic, and diabetic ranges === The 2010 American Diabetes Association Standards of Medical Care in Diabetes added the HbA1c ≥ 48 mmol/mol (≥6.5 DCCT %) as another criterion for the diagnosis of diabetes.
=== Semiconductors === Semiconductor intellectual property, a business model for licensing intellectual property Single in-line package, for packaging electronic components System in package, chip technology, also known as a chip stack multi-chip module Silicon photonics, silicon semiconductor used as an optical medium
Nidogen-1 (NID-1), formerly known as entactin, is a protein that in humans is encoded by the NID1 gene. Both nidogen-1 and nidogen-2 are essential components of the basement membrane alongside other components such as type IV collagen, proteoglycans (heparan sulfate and glycosaminoglycans), laminin and fibronectin.
The vaginal opening (also known as the vaginal introitus and the Latin ostium vaginae) is at the posterior end of the vulval vestibule, behind the urethral opening. The term introitus is more technically correct than "opening", since the vagina is usually collapsed, with the opening closed. The opening to the vagina is normally obscured by the labia minora (inner lips), but may be exposed after vaginal delivery. The hymen is a thin layer of mucosal tissue that surrounds or partially covers the vaginal opening. The effects of intercourse and childbirth on the hymen vary. Where it is broken, it may completely disappear or remnants known as carunculae myrtiformes may persist. Otherwise, being very elastic, it may return to its normal position. Additionally, the hymen may be lacerated by disease, injury, medical examination, masturbation or physical exercise. For these reasons, virginity cannot be definitively determined by examining the hymen.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.